


CEPI

CEPI funding opportunities

GLOHRA webinar on
22 November 2023





CEPI 2.0

100
day
aspiration


CEPI



Prepare



Transform



Connect

To develop a safe and effective vaccine in 100 days from the moment that a pathogen is sequenced and/or the need for a vaccine is recognised to initial availability for use.

CEPI's vaccine portfolio

50+

Investments in
vaccine candidates or
platform technologies

3

Chikungunya

14

SARS-CoV-2

*4 WHO EUL. 3
approved for
domestic use. 1
active.

6

Lassa Fever

4 active

13

Broadly
protective CoV
vaccines

11 active

4

MERS-CoV

3 active

2

Rift Valley
Fever

4

Nipah Virus

3 active


5

Disease X
platforms

CEPI's response to COVID-19




Early MERS and
Disease X
investments



Establishing
one of the
largest vaccine
portfolios



Harmonising
assessment of
COVID-19
vaccine data



Tracking SARS-
CoV-2 variants



Advancing broadly
protective
coronavirus
vaccines



Enabling equitable access
through COVAX

COVAX

- Co-led by CEPI, Gavi, WHO and UNICEF to develop and deliver vaccines to the world.
- Mechanism pooled financial resources to develop vaccines, purchase at scale, and invest up-front in manufacturing.
- Delivered almost **2 billion doses of vaccine to 146 countries to date**. Over 90% were provided to 92 lower income countries at no cost.
- Helped avert 2.7 million deaths in AMC countries by end of 2022.



CEPI networks serve the global vaccine ecosystem


Future vision: CEPI is partnering with and strengthening laboratories situated in locations that will serve the local vaccine ecosystem.

Strategic support to preclinical and clinical vaccine development studies, manufacturing activities and clinical trial sites.


Animal models Network: Original partners, pending

Centralized Lab Network: Original partners, pending

Manufacturing Network: Original partners, pending



A shared global endeavour



CEPI's portfolio comprises a global base of:

- 250+ awardees/sub/awardees
- In 50+ countries
- Across vaccine development, manufacturing enabling science and cross-cutting activities

>> Special focus on the Global South

ACCESS lies at the heart of our plan




Equitable access is central to everything CEPI does.

Hence, equitable access conditions are part of every funding agreement.

#100DaysMission

CEPI has made significant investments in a growing R&D portfolio



Since 2017

- **Over 35 R&D funding calls for proposals**
- **52 investments** in vaccine candidates or platform technologies
- Including **14 COVID-19 vaccine candidates** with hundreds of millions of doses for global use, and the world's leading portfolio of **broadly protective coronavirus vaccines**.
- **World largest centralised lab network** to support priority pathogen vaccine studies and multiple other enabling-science activities

Launch of selected Calls for Proposals



Disease X: The potential to jump species




This is not the first pandemic of the 21st century and it will not be the last.



We don't know where or when Disease X will emerge, but we know that it will.



Zoonotic spillover events have caused some of the world's most deadly outbreaks – HIV, Ebola, SARS, and likely COVID-19.



The need



Speed

- Development of a vaccine within 100 days from start of an outbreak



Safety/Efficacy

- Prevention of viral transmission
- Protection against related viruses/viral families
- Rapid-onset protection (< 2 weeks after first dose)
- Long-duration protection (\geq 1 year)
- Immunogenicity comparable to licensed vaccines
- Safety comparable to licensed vaccines




Accessibility


- Single primary dose
- Affordability (< \$2 USD per dose)
- Thermostability (\geq 2-8°C for \geq 12 months)
- Manufacturing at scale and in region

The opportunity

TechTalks and Scouting Meetings (n=405)




Vaccine Candidates and Platforms



Credit: Gladys Macharia

Several focus areas and options for funding



Introducing a new approach to funding innovation based on lessons learned



Innovations can appear at any time, in unexpected places

→ Broad scope, targeting problems to be solved rather than specific technologies



If we don't act quickly, we risk missing opportunities



Highly innovative, early-stage opportunities require an appetite for risk

→ Exploratory proposals with more focus on potential impact than feasibility




Global South developers often struggle to compete for CEPI CfPs

→ Exploratory Awards can fill data gaps, support earlier stage work

Vaccine & Biologics Innovations CfP – Overall Objective


Advance innovations with the potential to transform outbreak response



Innovative vaccine platforms (FA1) that can transform outbreak response



Vaccine candidates (FA2) for priority pathogens and viral families



Innovative manufacturing technologies (FA3) to improve vaccine scalability and equitable access

- Find the call for proposals here: https://cepi.net/get_involved/cfps/
- Please read the call text carefully, and flag your potential interest when you have identified the focus area matching your plans the best to the email: innovations.cfp@cepi.net
- We are happy to answer any questions regarding the calls for proposal or how CEPI operates.

The logo for the Coalition for Epidemic Preparedness Innovations (CEPI). It features the letters 'C', 'E', 'P', and 'I' in a white, sans-serif font. The letter 'E' is stylized with a white dot in its center. The background is a dark blue gradient with two large, overlapping circular shapes in shades of red and orange on the left and right sides.

CEPI

www.cepi.net

@CEPIvaccines